According to many investigations, brigatinib was an effective and safe targeted drug for advanced ALK-positive non-small-cell lung cancer[21–23] And the result of AUTODOCK showed brigatinib had a nice docking with MET. Here, ALK is linked to non-small cell lung carcinoma.